Description: Changes to AG 43 and what that might mean for tax purposes. Also, summary of IRS Notice 2016-63 (provides safe harbor tax guidance on use of 2017 CSO tables).

Description: A copy of a recent 1967 ruling of the New York Insurance Department on the treatment of graded premium policies in Schedule Q.

Description: VM-22 was first introduced into the Valuation Manual in 2018. A number of changes have been made since its introduction, with more expected on the way. This article compares valuation requirements for income annuities pre- and post-VM-22, discusses technical and implementation implications with regards to VM-22 (including comparison with New York Regulation 213), and considers future revisions.

Description: The article provides an introduction to tax accounting for U.S. life insurance companies, with a focus on NAIC statutory accounting concepts. The author discusses permanent and temporary differences, the current tax provision, and deferred tax accounting requirements, including admissibility testing under SSAP No. 101.

Description: Panelists consider the future environment of the valuation actuary in the U.S., the current environment in Canada and elsewhere, and the likely future methods of determining financial solvency in the U.S. From the 1988 Record of Society of Actuaries, Vol. 14, No. 4A.

Description: This session discussion is about tools, techniques, and methods used by the health valuation actuary HVA in dealing with business projections, cash-flow analysis, valuation on nonguaranteed premium business, target surplus analysis, reinsurance and claim reserves. From Record of Society of Actuaries Vol. 18, No. 1A.

Description: 1993 SOA Annual Meeting, New York. This session provided an update on the appointed actuary. Topics included: 1. Provided preliminary results of a 1992 cash-flow-testing survey that was sent to a number of life companies in the U.S. 2. A discussion of the position taken by one actuary who did not do cash-flow testing in forming an opinion for his company's 1992 annual statement. 3. How to deal with failed scenarios. 4. The evolution of the appointed actuary's role at MetLife. 5. How the process currently works at MetLife. 6. Insights on where MetLife sees the process going.

Description: 1993 SOA Annual Meeting, New York. This session discussion is about the impact of RBC on product design. Topics included: 1. An overview of the regulatory aspects of RBC. 2. How to incorporate RBC into the pricing of insurance products. 3. The small company perspective 4. The application of marginal RBC analysis. 5. A preliminary analysis on RBC covariance between product lines.

Description: From a session at the 2000 Valuation Actuary Symposium held in Washington DC, September 14-15, 2000 In this session, panelists discussed how they have leveraged cash-flow testing to: • Influence investment decisions • Analyze risks • Expand Cash flow testing models to meet management requirements • Provide relevant information to regulators and rating agencies Panelists discussed the enhancements required to meet these needs and provide guidance on communication of results to a nontechnical audience.

Description: This presentation is a panel discussion, session number 2PD, from the 2002 Valuation Actuary Symposium, held September 19-20 in Lake Buena Vista, FL. The panelists introduce major life and annuity statutory and GAAP valuation issues, which are covered in depth at subsequent sessions. There is also a brief update on activities of the International Accounting Standards Board [IASB]. Statutory topics include the draft National Association of Insurance Commissioners [NAIC] Actuarial Guideline MMMM for variable products with guaranteed living benefits, amendments to the Actuarial Opinion and Memorandum Regulation [AOMR], Regulation XXX mortality factors, and codification update, potential changes to the Standard Valuation Law, risk-based capital, and adoption of the 2001 CSO Mortality Table for valuation. GAAP topics include Statement of Financial Reporting Standards [SFAS] 133, 141, and 142, and two draft AICPA Statements of Position [SOP], one on nontraditional, long-duration products and another on internal replacements. Discussion from participants is included.